We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of CNCE yet.

CNCE Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2023, worth a combined $0 — down 100% from $203M a quarter earlier.

Sellers outnumbered buyers: 85 funds closed out of CNCE and 0 opened new positions — a net loss of 85 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Kynam Capital Management, exiting entirely with an estimated $25.8M sold.

  • 0 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $0 of Concert Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2023 and 85 closed out, a net change of -85 holders.
  • The largest Concert Pharmaceuticals, Inc. seller in Q1 2023 was Kynam Capital Management, an estimated $25.8M sold.

Based on aggregated 13F filings for Q1 2023.